93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
December 05, 2025 20:00 ET | Source: ORIC Pharmaceuticals Highly differentiated 1L preliminary systemic activity of 67% ORR and 100%…
December 05, 2025 01:00 ET | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product…
MUMBAI, India and PUNE, India, Dec. 1, 2025 /PRNewswire/ -- Krisala Developers, one of Maharashtra's most trusted and award-winning real…
Austin, TX, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Crypto Mondays Austin announces Regenerative Wealth, an innovative gathering that merges technology,…
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs…
November 09, 2025 09:00 ET | Source: Medera Inc. BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…